KRAS and large cell carcinoma: We also sequenced 19 large cell carcinoma samples resected from November 2007 to May 2012 to detect mutations in EGFR kinase domain, HER2 kinase domain, KRAS, BRAF, ALK, RET and AKT1. There were 3 (15.8%) EGFR mutations and 4 (21.1%) KRAS mutations (Figure 2C).